News

Sales, profits increase for Dr. Reddy’s in Q2

BY Alaric DeArment

HYDERABAD, India — Dr. Reddy’s Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

The Indian generic drug maker said the second-quarter sales represented a 21% increase over second quarter 2011. Sales from global generics were $329 million for the quarter, an 18% increase over second quarter 2011, driven mostly by growth in North America and Russia.

Profits for the quarter were $63 million, a 7% increase over second quarter 2011.

Other highlights during the quarter included 28 new generic product launches and 17 regulatory filings, as well as the Food and Drug Administration’s approval of its generic version of Eli Lilly’s schizophrenia and bipolar disorder drug Zyprexa (olanzapine).


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

DannyHaszard says:
Oct-25-2011 04:48 pm

Zyprexa issues continue PTSD treatment for Veterans found ineffective. Eli Lilly Zyprexa Olanzapine. The use of powerful antipsychotic drugs has increased in children as young as three years old. Weight gain, increases in triglyceride levels and associated risks for diabetes and cardiovascular disease. The average weight gain (adults) over the 12 week study period was the highest for Zyprexa—17 pounds. You’d be hard pressed to gain that kind of weight sport-eating your way through the holidays.One in 145 adults died in clinical trials of those taking the antipsychotic drug Zyprexa. This was Lilly's # 1 product over $ 4 billion per year sales,moreover Lilly also make billions on drugs that treat the diabetes often that has been caused by the zyprexa! --- Daniel Haszard Zyprexa victim activist and patient who got diabetes from it. http://www.zyprexa-victims.com

TRENDING STORIES

News

Supervalu, Save-A-Lot reiterate commitment to combating food deserts

BY Allison Cerra

CHICAGO — As part of its continued agreement with the Partnership for a Healthier America, Supervalu announced that it is on track to eliminate food deserts nationwide.

At an event held Tuesday that included such attendees as first lady Michelle Obama and Chicago mayor Rahm Emanuel, Supervalu announced that its wholly owned subsidiary Save-A-Lot will open a new store in Chicago’s Lawndale neighborhood at the end of November in order to position the area as a food oasis.

Supervalu previously announced plans to open 250 new Save-A-Lot stores in areas across the United States where there is limited or no access to affordable, healthy, fresh foods. Since then, the company has opened 14 new Save-A-Lot stores in food deserts throughout the country. Based on U.S. Department of Agriculture guidelines, Save-A-Lot currently operates more than 400 of its nearly 1,300 stores in areas that otherwise would be recognized as being in or near a food desert, the company said.

"Supervalu and its network of stores, including our Save-A-Lot subsidiary, are committed to bringing healthy, affordable food offerings to customers here in Chicago and throughout the United States," Supervalu president and CEO Craig Herkert said. "We appreciate the tremendous leadership shown by first lady Michelle Obama and mayor Emanuel to address this important issue.

"In addition to food access and affordability, we are taking steps to help consumers make the best food choices possible for themselves and their families," Herkert said. "According to research, nearly 80 percent of customers say they need help and advice around planning, shopping, cooking and preparing food. As a leading grocery retailer, we’re ideally positioned to help them by providing the programs, resources and tools they need to achieve a healthy diet."


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Sanofi appoints David Meeker as CEO of Genzyme

BY Alaric DeArment

PARIS — Sanofi has appointed David Meeker as CEO of Genzyme, the French drug maker said.

Sanofi bought the Cambridge, Mass.-based biotech manufacturer for $20.1 billion earlier this year.

"After working closely with David over the past six months, I am confident that he is the best person to lead Genzyme," Sanofi CEO Christopher Viehbacher said. "David’s commitment to employees, physicians and patients has been a key success factor in the successful integration of Genzyme as part of the Sanofi Group."

Meeker began working for Genzyme in 1994 and was appointed COO in 2009. He will assume the position on Nov. 1.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES